Learn more about Janssen’s COVID-19 response and our continued support to help patients afford and access our medicines.[x]

Start with OPSUMIT® (macitentan) to reduce the risks of disease progression and hospitalization for PAH1

In the treatment of pulmonary arterial hypertension (PAH, WHO Group I)

Learn more about OPSUMIT clinical data

View overall results from the SERAPHIN pivotal trial

Looking for patient enrollment resources?

Get patients started on OPSUMIT

See SERAPHIN PAH-related hospitalization data

View PAH-related hospitalization data

Need downloadable resources?

View our library of downloadable materials for HCPs and patients

Explore SERAPHIN PAH-CTD subgroup data

View PAH-CTD subgroup post hoc analyses

Watch patient and HCP perspectives on PAH

Access the video library

PAH=pulmonary arterial hypertension; PAH-CTD=PAH associated with connective tissue disease; SERAPHIN=Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve CliNical Outcome; WHO=World Health Organization.